H2 2020 Asthma Pipeline Review – Mergers and Acquisitions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asthma – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

The report provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 16, 42, 36, 4, 126, 31 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 30 and 9 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
3. Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
4. Classify potential new clients or partners in the target demographic.
5. Develop tactical initiatives by understanding the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Asthma – Overview
• Asthma – Therapeutics Development
• Asthma – Therapeutics Assessment
• Asthma – Companies Involved in Therapeutics Development
• Asthma – Drug Profiles
• Asthma – Dormant Projects
• Asthma – Discontinued Products
• Asthma – Product Development Milestones
• Appendix

Companies Mentioned

• 2A Pharma AB
• 3SBio Inc
• 4D Pharma Plc
• AB Science SA
• AbbVie Inc
• Abeome Corp
• Adamis Pharmaceuticals Corp
• Adare Pharma Solutions
• Advagene Biopharma Co Ltd
• Aerami Therapeutics
• Airbase Breathing Co LLC
• Akeso Inc
• Aldeyra Therapeutics Inc
• Algomedix Inc
• ALK-Abello AS
• Allergan Ltd
• AllerGen NCE Inc
• Allergy Therapeutics Plc
• Amgen Inc
• Amphastar Pharmaceuticals Inc
• AnGes Inc
• Antisense Therapeutics Ltd
• Apollo Therapeutics LLC
• Aquilon Pharmaceuticals SA
• ArcticZymes Technologies ASA
• Argenx SE
• Artax Biopharma Inc
• Artizan Biosciences Inc
• ASIT Biotech SA
• Aslan Pharmaceuticals Ltd
• AstraZeneca Plc
• Cumberland Pharmaceuticals Inc
• Cynata Therapeutics Ltd
• Cytokinetics Inc
• Daewoong Pharmaceutical Co Ltd
• Daiichi Sankyo Co Ltd
• Defensin Therapeutics ApS
• Dnarx LLC
• EffectorBio Inc
• Eleusis Ltd
• EmphyCorp Inc
• Energenesis Biomedical Co Ltd
• Enzychem Lifesciences Corp
• ethris GmbH
• EURRUS Biotech GmbH
• Evelo Biosciences Inc
• Exotect LLC
• F. Hoffmann-La Roche Ltd
• Fibrotherapeutics Inc
• Foresee Pharmaceuticals Co Ltd
• GeneFrontier Corp
• Genentech USA Inc
• Jiangsu Hengrui Medicine Co Ltd
• JiangSu Qyuns Therapeutics Co Ltd
• JW Pharmaceutical Corp
• Kashiv BioSciences LLC
• KBP BioSciences Co Ltd
• Kissei Pharmaceutical Co Ltd
• Kither Biotech Srl
• KLUS Pharma Inc
• Knopp Biosciences LLC
• KoBioLabs Inc
• Korea United Pharm Inc
• Kyowa Kirin Co Ltd
• Laboratorios LETI SLU
• Landos Biopharma Inc
• Laurel Therapeutics
• Lead Discovery Center GmbH
• Lignamed LLC
• Liminal BioSciences Inc
• Longevity Biotech Inc
• Mabpharm Ltd
• Mabtech Ltd
• Mabwell Shanghai Bioscience Co Ltd
• Mariposa Health Ltd
• MD Healthcare Inc
• Medicenna Therapeutics Corp
• Mercia Pharma Inc
• Merck & Co Inc
• MitoImmune Therapeutics Inc
• Translational Biosciences
• Trio Medicines Ltd
• Tunitas Therapeutics Inc
• United Biomedical Inc
• United BioPharma Inc
• Vactech Oy
• Vanworld Pharmaceutical (Rugao) Company Ltd
• Vascular BioSciences
• Vasomune Inc
• Vectura Group Plc
• Verona Pharma Plc
• Vicenna Pharmaceuticals Inc
• Yuhan Corp
• Zhejiang Hisun Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mi1dxk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900